Abstract
Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haases “neuroleptic threshold” concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp “all-or-none” threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, individualized dose, atypical antipsychotic agents
Current Neuropharmacology
Title: Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Volume: 7 Issue: 4
Author(s): R. Miller
Affiliation:
Keywords: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, individualized dose, atypical antipsychotic agents
Abstract: Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haases “neuroleptic threshold” concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp “all-or-none” threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.
Export Options
About this article
Cite this article as:
Miller R., Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II, Current Neuropharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157015909790031184
DOI https://dx.doi.org/10.2174/157015909790031184 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Subject Index to Volume 4
Current Topics in Medicinal Chemistry The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Targeting the Progression of Parkinsons Disease
Current Neuropharmacology The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology